AUPH
Price:
$8.98
Market Cap:
$1.29B
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.[Read more]
Industry
Biotechnology
IPO Date
2014-09-03
Stock Exchange
NASDAQ
Ticker
AUPH
According to Aurinia Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -59.87. This represents a change of -191.89% compared to the average of 65.15 of the last 4 quarters.
The mean historical PE Ratio of Aurinia Pharmaceuticals Inc. over the last ten years is -9.78. The current -59.87 PE Ratio has changed 61.14% with respect to the historical average. Over the past ten years (40 quarters), AUPH's PE Ratio was at its highest in in the June 2024 quarter at 272.46. The PE Ratio was at its lowest in in the December 2020 quarter at -54.22.
Average
-9.78
Median
-7.68
Minimum
-16.50
Maximum
-3.18
Discovering the peaks and valleys of Aurinia Pharmaceuticals Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 191.23%
Maximum Annual PE Ratio = -3.18
Minimum Annual Increase = -65.34%
Minimum Annual PE Ratio = -16.50
Year | PE Ratio | Change |
---|---|---|
2023 | -16.50 | 191.23% |
2022 | -5.67 | -65.34% |
2021 | -16.35 | 2.46% |
2020 | -15.96 | 4.86% |
2019 | -15.22 | 68.76% |
2018 | -9.02 | 71.12% |
2017 | -5.27 | 65.67% |
2016 | -3.18 | -25.48% |
2015 | -4.27 | -32.66% |
2014 | -6.34 | -34.78% |
The current PE Ratio of Aurinia Pharmaceuticals Inc. (AUPH) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-12.84
5-year avg
-13.94
10-year avg
-9.78
Aurinia Pharmaceuticals Inc.’s PE Ratio is less than Viking Therapeutics, Inc. (-47.37), less than Axsome Therapeutics, Inc. (-13.47), less than Madrigal Pharmaceuticals, Inc. (-13.08), less than ImmunoGen, Inc. (322.18), less than Seres Therapeutics, Inc. (-5.75), less than Exelixis, Inc. (20.69), greater than TG Therapeutics, Inc. (-324.87), less than BioXcel Therapeutics, Inc. (-0.21), less than Sarepta Therapeutics, Inc. (95.43), less than Hepion Pharmaceuticals, Inc. (-0.15), less than PTC Therapeutics, Inc. (-7.70), less than Intercept Pharmaceuticals, Inc. (0), greater than Terns Pharmaceuticals, Inc. (-91.78), less than Akero Therapeutics, Inc. (-5.12), less than Reata Pharmaceuticals, Inc. (-8.36), less than null (-20.07),
Company | PE Ratio | Market cap |
---|---|---|
-47.37 | $4.72B | |
-13.47 | $4.22B | |
-13.08 | $6.80B | |
322.18 | $8.73B | |
-5.75 | $163.91M | |
20.69 | $9.66B | |
-324.87 | $5.01B | |
-0.21 | $17.42M | |
95.43 | $11.64B | |
-0.15 | $3.48M | |
-7.70 | $3.50B | |
0 | $794.69M | |
-91.78 | $492.65M | |
-5.12 | $1.99B | |
-8.36 | $6.57B | |
-20.07 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aurinia Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aurinia Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aurinia Pharmaceuticals Inc.'s PE Ratio?
How is the PE Ratio calculated for Aurinia Pharmaceuticals Inc. (AUPH)?
What is the highest PE Ratio for Aurinia Pharmaceuticals Inc. (AUPH)?
What is the 3-year average PE Ratio for Aurinia Pharmaceuticals Inc. (AUPH)?
What is the 5-year average PE Ratio for Aurinia Pharmaceuticals Inc. (AUPH)?
How does the current PE Ratio for Aurinia Pharmaceuticals Inc. (AUPH) compare to its historical average?